Home/Pipeline/Tysabri

Tysabri

Multiple Sclerosis

MarketedActive

Key Facts

Indication

Multiple Sclerosis

Phase

Marketed

Status

Active

Company

Royalty Pharma

About Royalty Pharma

Royalty Pharma is a pioneer and dominant leader in the biopharmaceutical royalty financing sector, having deployed over $25 billion in capital since its 1996 founding. Its mission is to fund the next wave of biopharma innovation by providing non-dilutive capital to partners in exchange for a share of future royalty streams. The company's strategy centers on building a diversified portfolio of royalties across therapeutic areas and development stages, leveraging deep scientific and financial expertise to structure bespoke deals that fuel R&D while generating predictable, long-duration cash flows for investors.

View full company profile

Therapeutic Areas

Oncology Cystic Fibrosis HIV Cardiovascular Autoimmune Diseases Neurology

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active
REBIF (interferon beta-1a)	EMD Serono	Approved	Active (Lifecycle Management)